Restoret showed promising safety and efficacy results at 12 weeks in patients with treatment-naive diabetic macular edema and treatment-naive neovascular age-related macular degeneration, according to a press release from EyeBio.
“Restoret has shown visual and anatomic improvements in patients with DME and NVAMD,” David R. Guyer, MD, CEO of EyeBio, told Healio. “What is most unique is that Restoret works by a completely novel mechanism of action that has not been tested in the eye before. This allows for product differentiation compared to anti-VEGF standard of care both as a